• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bone Biologics Corp

    9/26/25 5:00:42 PM ET
    $BBLG
    Industrial Specialties
    Health Care
    Get the next $BBLG alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the U.S. Securities and Exchange Commission on September 26, 2025

     

    Registration No. 333-___

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE

    SECURITIES ACT OF 1933

     

    BONE BIOLOGICS CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware 42-1743430

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    2 Burlington Woods Drive, Suite 100

    Burlington, MA 01803

    (Address of principal executive offices) (Zip code)

     

     

     

    Bone Biologics Corporation 2015 Equity Incentive Plan

    (Full title of the plan)

     

     

     

    Jeffrey Frelick

    Chief Executive Officer

    Bone Biologics Corporation

    2 Burlington Woods Drive, Suite 100

    Burlington, MA 01803

    (Name and address of agent for service)

     

    (781) 552-4452

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Alexander R. McClean, Esq.

    Harter Secrest & Emery LLP

    1600 Bausch & Lomb Place

    Rochester, NY 14604

    (585) 231-1248

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed by Bone Biologics Corporation (the “Company”) to register an additional 5,000,000 shares (the “Additional Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), issuable under the Bone Biologics Corporation 2015 Equity Incentive Plan, as amended (the “Plan”). The Additional Shares are in addition to the shares of Common Stock previously registered for issuance under the Plan pursuant to the Company’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “SEC”) on (i) August 4, 2016 (File No. 333-212890) and (ii) September 15, 2023 (File No. 333-274545) (collectively, the “Prior Registration Statements”).

     

    The Additional Shares being registered hereby reflect the 1-for-6 reverse stock split effective June 10, 2025.

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities. Pursuant to such instruction, the contents of the Prior Registration Statements are incorporated by reference and made part of this Registration Statement, except to the extent modified, superseded, or amended by the information set forth herein.

     

    2

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents previously filed by the Company with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference in this Registration Statement (except for portions thereof furnished or otherwise not filed with the SEC pursuant to Items 2.02 or 7.01 of Form 8-K and corresponding information furnished under Item 9.01 of Form 8-K, which are deemed not to be incorporated by reference into this Registration Statement):

     

      ● Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 26, 2025;
         
      ● Our Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025 filed with the SEC on May 12, 2025 and August 14, 2025, respectively;
         
      ● Our Current Reports on Form 8-K filed with the SEC on April 1, 2025, April 11, 2025, May 30, 2025, June 6, 2025, June 26, 2025, and June 30, 2025; and
         
      ● The description of the Common Stock incorporated by reference to our Registration Statement on Form 8-A that was filed with the SEC on October 8, 2021, Exhibit 4.5 to Amendment No. 1 to our Annual Report for the fiscal year ended December 31, 2022 on Form 10-K/A filed with the SEC on November 20, 2023, and any amendment or report filed for the purpose of updating such description.

     

    In addition to the foregoing, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement (except for the portions thereof furnished or otherwise not filed with the SEC which are deemed not to be incorporated by reference into this Registration Statement), but prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits

     

    Exhibit No.   Description
         
    4.1   Amended and Restated Certificate of Incorporation of Bone Biologics Corporation (incorporated herein by reference to Exhibit 3.1(i) to the Current Report on Form 8-K filed September 25, 2014)
         
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bone Biologics Corporation filed October 8, 2021 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed October 15, 2021)
         
    4.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation filed June 5, 2023 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 6, 2023)
         
    4.4   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation filed December 14, 2023 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed December 18, 2023)

     

    II-1

     

     

    4.5   Certificate of Amendment to Amended and Restated Certification of Incorporation of Bone Biologics Corporation filed June 5, 2025 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 6, 2025)
         
    4.6   Amended and Restated Bylaws of Bone Biologics Corporation (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 8, 2022)
         
    4.7   Amendment No. 1 to the Amended and Restated Bylaws of Bone Biologics Corporation (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on October 24, 2023)
         
    5.1*   Opinion of Harter Secrest & Emery LLP
         
    23.1*   Consent of Independent Registered Public Accounting Firm, Weinberg & Company, P.A.
         
    23.2*   Consent of Harter Secrest & Emery LLP (included in the opinion filed as Exhibit 5.1)
         
    24.1*   Power of Attorney (included on the signature page of this registration statement)
         
    99.1+   Bone Biologics Corporation 2015 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed January 4, 2016)
         
    99.2+   First Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan (incorporated herein by reference to Annex B to the registrant’s Proxy Statement on Schedule 14A filed August 3, 2023)
         
    99.3+   Second Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed May 30, 2025)
         
    107*   Filing Fee Table

     

    * Filed herewith.

    + Management contract or compensatory arrangement.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Burlington, Commonwealth of Massachusetts, on September 26, 2025.

     

      BONE BIOLOGICS CORPORATION
         
      By: /s/ Jeffrey Frelick
      Name: Jeffrey Frelick
      Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below appoints Jeffrey Frelick and Deina H. Walsh, and each of them, each of whom may act without the joinder of the other, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him and her and in his or her name, place and stead, in any and all capacities to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jeffrey Frelick   Chief Executive Officer (Principal Executive Officer)   September 26, 2025
    Jeffrey Frelick        
             
    /s/ Deina H. Walsh   Chief Financial Officer (Principal Financial Officer and   September 26, 2025
    Deina H. Walsh   Principal Accounting Officer)    
             
    /s/ Bruce Stroever   Director   September 26, 2025
    Bruce Stroever        
             
    /s/ Robert Gagnon   Director   September 26, 2025
    Robert Gagnon        
             
    /s/ Siddhesh Angle   Director   September 26, 2025
    Siddhesh Angle        
             
     /s/ Phillip Meikle   Director   September 26, 2025
    Phillip Meikle        

     

    II-3

     

    Get the next $BBLG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBLG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BBLG
    SEC Filings

    View All

    SEC Form S-8 filed by Bone Biologics Corp

    S-8 - Bone Biologics Corp (0001419554) (Filer)

    9/26/25 5:00:42 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bone Biologics Corp (0001419554) (Filer)

    9/4/25 7:05:25 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form EFFECT filed by Bone Biologics Corp

    EFFECT - Bone Biologics Corp (0001419554) (Filer)

    9/3/25 12:15:04 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Meikle Phillip Terry Ii

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:30 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Angle Siddhesh Rajendra

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:24 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Stroever Bruce

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:18 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM). NELL-1 has several unique prope

    9/4/25 7:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. The Company is underta

    9/3/25 7:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Announces Closing of $5.0 Million Public Offering

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants have an exercise price of $4.00 per share, are exercisable immediately upon issu

    6/30/25 4:10:00 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

    Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

    10/21/24 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

    Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

    1/11/24 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/13/24 11:14:34 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    6/28/24 4:15:43 PM ET
    $BBLG
    Industrial Specialties
    Health Care